Tag: Motley Fool Australia

Investing in ASX shares as a first-timer is exciting. You can finally put some hard-earned cash to work and start building your financial future.

ASIC recently reported a noticeable increase in trading from everyday investors like you and me in the March bear market. That’s great news as more people are gaining an interest in the Aussie share market.

However, investing is not for everyone. How, where and when you invest will vary depending on your age, net worth, future plans and many other factors.

Here’s a quick guide to check whether you’re ready to invest in ASX shares in 2020.

Pay off your debts

It’s easy to get ahead of yourself when looking to invest in ASX shares. However, paying off personal and unproductive debt like credit cards or auto loans is often a better use of money.

Credit card interest rates can be in excess of 20% per annum. You’re unlikely to generate that sort of return consistently with ASX shares. 

Paying off expensive, interest-accruing debts means less obligations to the banks. This will generally mean less stress and more freedom to invest in ASX shares as you like.

Build up an emergency fund

One thing that people are feeling right now is FOMO. The S&P/ASX 200 Index (ASX: XJO) has climbed around 34% higher since 23 March. 

That means many first time investors are worried they’re missing out on potential gains. But as a long-term investor, you don’t want to be forced to sell.

It’s a wise move to build up an emergency fund of 3-12 months worth of living expenses, depending on your circumstances. Having this liquid (i.e. cash) emergency fund means you can invest in ASX shares knowing you can handle the odd unexpected expense.

There’s nothing worse than buying a hot stock like Afterpay Ltd (ASX: APT) and being forced to sell at a bad time because of liquidity issues.

Buy your favourite ASX shares!

Once you’re debt-free and have a decent emergency fund, it’s time to look at the markets.

If you’re a first-timer, I think diversification is key. You want to spread your portfolio risk across a number of ASX shares, to begin with.

That could mean a low cost, diversified exchange-traded fund (ETF) like BetaShares Australia 200 ETF (ASX: A200) could be a good option.

The fund has a management fee of just 0.07% per annum and attempts to track the benchmark index.

If you’re after more concentrated positions, blue-chip shares like BHP Group Ltd (ASX: BHP) or Commonwealth Bank of Australia (ASX: CBA) have historically been portfolio staples.

Foolish takeaway

While it’s easy to get excited as a first-time investor, it’s best to take a step back and breathe.

The share market will still be there in a few months’ time. There will still be good ASX shares to buy.

By paying down your debts and building up an emergency fund, you will be able to confidently invest in your favourite companies knowing that you’re well set up for the future.

More reading

• Why Afterpay, BHP, Cann, & Mesoblast shares are tumbling lower
• Should you buy ASX retail shares in July?
• Are ASX 200 shares overvalued right now?
• Is the Brambles share price a hidden buy?
• Is the Tassal share price a potential outperformer?

The post Are you ready to invest in ASX shares? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/39gj0Dy

After days of consecutive growth, the Immuron Limited (ASX: IMC) share price is falling today following announcement of its registered direct offering. The share price is currently down 27% (at the time of writing) on the news. However, recent days have seen the Immuron share price on a wild ride, up 249% yesterday before today’s falls. Immuron is an Australian biopharmaceutical company focused on developing and commercialising oral medicine for the prevention and treatment of gut mediated pathogens.

Why is the Immuron share price falling?

The Immuron share price is today falling following the announcement that the company is raising US$20 million through a registered direct offering. The company announced it has entered into agreements with several healthcare-focused institutional investors for their participation in a registered direct offering of 1,066,668 American Depositary Shares (ADSs). Each of these ADSs represents 40 of the company’s ordinary shares. The price of these ADSs is $18.75. This is a premium with the company’s US dual listed cousin Immuron Ltd/S ADR (NASDAQ: IMRN) currently trading at US$14.81. However the large drop in the Immuron share price is no doubt due to the considerable dilution of the share value the offering causes. The offering is set to close around 23 July.

Immuron intends to use the net proceeds from this offering to fund its Research and Development and preclinical and clinical programs. The funding is also being used to support marketing initiatives surrounding the company’s flagship product, Travelan, and provide ongoing working capital.

What now for Immuron?

In recent days there has been plenty of news out of Immuron. On Monday, the Immuron share price shot 11% higher after receiving FDA guidance for its new developmental drug. Subsequently in further exciting news, the Immuron share price rose nearly 250% yesterday as its flagship drugs, Travelan and Protectyn, demonstrated antiviral activity against COVID-19 in laboratory testing. It is not surprising today that we are seeing a pull back in the share price as it becomes heavily diluted. While this may be seen as a negative, it can also be seen as investors having confidence in the company moving forward, investing their money at higher prices.

More reading

• Immuron share price shoots 90% higher on potential COVID-19 treatment news
• Immuron share price shoots 6% higher after receiving FDA guidance for new drug

The post Immuron share price falls 27% on registered direct offering appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32HHynZ

Data is the key for ASX retail shares in 2020. That’s what I think is the big message after the value of Australia’s retailers surged on Tuesday.

Positive news about coronavirus vaccine candidates pushed the S&P/ASX 200 Index (ASX: XJO) as a whole 2.6% higher on Tuesday.

However, ASX retail shares received a particularly strong boost from the Federal Government’s JobKeeper and JobSeeker extensions.

What’s happening with JobKeeper and JobSeeker?

Prime Minister Scott Morrison announced a range of changes to the existing stimulus programs.

JobKeeper payments will be reduced to $1,200 for full-time workers, down from $1,500 at the moment. That will run until the end of 2020 and then drop to $1,000 per fortnight from January 3.

The part-time worker payment will be reduced from $1,500 to $750 per fortnight after September before dropping to $650 per fortnight in 2021.

The new end date for ‘JobKeeper 2.0’ will be 28 March 2021.

The $550 JobSeeker supplement will be reduced to $250 per fortnight after September. That means total payments will be reduced from $1,115 to $815.

Why is that good news for ASX retail shares?

Yesterday I wrote about the potential impacts of this week’s action-packed spate of economic updates.

I wrote that an extension of JobKeeper and JobSeeker could help boost ASX 200 retail shares like JB Hi-Fi Limited (ASX: JBH) and Super Retail Group Ltd (ASX: SUL) higher.

That proved to be the case on Tuesday, with JB Hi-Fi shares surging 2.0% and Super Retail jumping 3.7%. Shares in retail REIT Scentre Group (ASX: SCG) also rocketed higher on the news, closing up 3.3% at $2.17 per share.

Retail billionaire Solomon Lew shared a similar view according to an article in the Australian Financial Review (AFR).

Mr Lew described ‘JobKeeper 2.0’ as a ‘big shot in the arm for the Australian workforce and broader economy’. Low unemployment is good for sales while the extra cash is helping retail stores continue operations.

Is now a good time to buy?

I think the answer to this really depends on the August earnings season. The JB Hi-Fi share price has climbed 14.2% this year on the back of strong sales. This says to me that investors are already pricing in a strong sales result in 2020.

However, the JobKeeper extension is good for business. That means more cash in the economy and less of a drain on expenditure.

If we see an Aussie retailer like Super Retail outperform with respect to earnings, I think ASX retail shares will finish the year strongly.

Any signs of persistent sales growth or operational streamlining could push ASX retail shares higher in August and September.

More reading

• Are you ready to invest in ASX shares?
• Are ASX 200 shares overvalued right now?
• Is the Brambles share price a hidden buy?
• Is the Tassal share price a potential outperformer?
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited. The Motley Fool Australia has recommended Scentre Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Should you buy ASX retail shares in July? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3jq6zd7

At the weekend I looked into how investments of $20,000 in a number of popular ASX shares fared over the last 10 years.

Given the success of these investments, I thought I would now look at a few shares which I feel investors ought to consider investing $20,000 into today for the next decade.

Here why I think these three ASX shares could provide strong returns for investors:

Altium Limited (ASX: ALU)

I think this electronic design software platform provider would be a great place to invest $20,000. I’m a big fan of Altium due to its exposure to the Internet of Things (IoT) boom. The rapidly growing IoT market should drive strong demand for its offering in the future. This is because the majority of these connected devices require software like Altium Designer and Altium 365 during the design process. Management appears confident in its outlook and is aiming for 100,000 subscriptions by FY 2025. This compares to the 50,000 subscriptions it is achieved in FY 2020. Combined with its other growing businesses, such as NEXUS and Octopart, I believe the future is bright for Altium.

Kogan.com Ltd (ASX: KGN)

Another ASX share to consider investing $20,000 into is Kogan. It is a growing ecommerce company and Australia’s version of Amazon. I think it is a great long term option for investors due to the growing popularity of its website and the continued shift to online shopping in the country. Prior to the pandemic, an estimated ~10% of retail spending was being made online in Australia. I expect this number to grow materially over the next decade and underpin strong sales and profit growth for Kogan.

NEXTDC Ltd (ASX: NXT)

A final ASX share for investors to consider investing $20,000 into is NEXTDC. I think the data centre operator’s shares could provide strong returns for investors over the 2020s due to its exposure to the rapidly growing cloud computing market. Thanks to the shift to the cloud, NEXTDC’s world class data centres have been experiencing a material increase in demand for capacity over the last few years. And with more infrastructure expected to shift over in the next decade, I believe it is well-positioned to profit greatly.

More reading

• Why Kogan and these popular ASX shares just hit record highs
• 5 things to watch on the ASX 200 on Wednesday
• ASX 200 jumps 2.6% on vaccine hopes and jobkeeper
• These ASX eCommerce shares are riding the online shopping wave
• My top 5 ASX growth shares to buy in FY 2021

James Mickleboro owns shares of NEXTDC Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Altium and Kogan.com ltd. The Motley Fool Australia has recommended Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Where to invest $20,000 into ASX shares right now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32GS3Yx

In morning trade the Beach Energy Ltd (ASX: BPT) share price is storming higher following the release of its fourth quarter update.

At the time of writing the energy producer’s shares are up 5% to $1.56.

How did Beach Energy perform in the fourth quarter?

Beach Energy reported fourth quarter total production of 6.8 MMboe, which brings its full year total production to a total of 26.7 MMboe. This represents a 2% increase on FY 2019 pro forma production of 26.2 MMboe.

FY 2020 oil production came in at 8.8 MMbbl, which was up 27% over FY 2019. This was in-line with its guidance of 8.7 MMbbl to 9.2 MMbbl.

However, despite its solid oil production, its overall production was a touch short of its full year production guidance.

Management explained that the effects of COVID-19 impacted the pace of new Western Flank well connections and gas demand during the quarter, resulting in its production being 1% below guidance.

Sales suffer from oil price collapse.

Beach Energy’s sales took a big hit during the fourth quarter following the collapse in oil prices.

It recorded fourth quarter sales revenue of $320 million, which was 26% lower than the prior quarter. This was driven by a 37% decline its realised oil price to $46.90 a barrel and offset slightly by cost saving measures.

Management continues to target further operating cost reductions to help offset the impact of lower oil prices. It is aiming for a 10% reduction in field operating costs/boe in FY 2021 relative to FY 2019 levels of $9.30/boe.

Overall, Beach Energy ended FY 2020 with $50 million net cash and access to $500 million in liquidity.

FY 2020 earnings to fall short of guidance.

In light of the above, management warned that it expects its FY 2020 underlying EBITDA to be marginally below its prior guidance of $1,175 million.

This is primarily due to oil/liquids prices, the impact of COVID-19 on production, and includes the costs relating to the Tawhaki 1 exploration well.

No guidance was given with today’s update. However, management intends to release its FY 2021 guidance and a five year outlook with its FY 2020 results in August.

More reading

• The worst performing ASX 200 oil stock is finally catching a break today
• Top brokers name 3 ASX shares to buy next week
• Why brokers think you should buy the slumping Woodside Petroleum share price today
• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Beach Energy share price storms higher despite Q4 sales slump appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/39fQ8LI

The Baby Bunting Group Ltd (ASX: BBN) share price has jumped higher following the release of its preliminary unaudited full year results.

In morning trade the baby products retailer’s shares are up 6% to $3.33.

How did Baby Bunting perform in FY 2020?

Baby Bunting was a strong performer in FY 2020 despite the disruption caused by the pandemic in the second half.

According to the release, Baby Bunting delivered total sales of approximately $405 million in FY 2020 This represents growth of around 12% and was driven by very strong second-half comparable store sales growth.

Comparable stores sales grew 10.5% during the second half, lifting full year comparable store sales growth to 4.9%. This was largely the result of its online business, with comparable store sales growth from its bricks and mortar stores coming in at 2.5% for the year.

Online sales (including click & collect) grew 39% during the year and now make up 14.5% of total sales.

In respect to earnings, Baby Bunting expects to report pro forma earnings before interest, tax, depreciation and amortisation (EBITDA) of between $33 million and $34 million. This represents growth of between 22% to 25% on FY 2019’s EBITDA result.

On the bottom line, the retailer is expecting to report pro forma net profit after tax of between $18.5 million and $19.5 million. This will be year on year growth of between 29% and 35%.

On a statutory basis, Baby Bunting expects a net profit after tax of between $9.5 million to $10.5 million. This will be down from $11.6 million a year earlier.

This statutory result includes the non-cash impact of employee equity incentive expenses, significant transformation project expenses, and the impairment of the carrying value of its investment in its digital commerce technologies. Pro forma EBITDA also excludes the impact of AASB 16 lease accounting.

“Very positive results”.

Baby Bunting’s CEO and Managing Director, Matt Spencer, was pleased with the company’s performance during these challenging times.

He said: “These are very positive results, in particular given the impact of the COVID-19 pandemic on communities in Australia. During the year, all of our stores remained open and our Team worked incredibly hard to adapt how we operated to ensure that we continue to support new and expectant parents in these challenging times. We have seen the business continue to grow in FY20 and I am confident that growth will continue in FY21.”

“As the ongoing restrictions in Melbourne and surrounding areas indicate, COVID-19 is likely to have an impact into FY21 in ways that may be unexpected. I am confident that our business can respond to new challenges as we did in the second half of FY20. To date, trading in FY21 has continued to be positive,” he added.

More reading

• Broker tips on how to invest for the August ASX reporting season

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Baby Bunting share price jumps after reporting strong growth despite COVID-19 appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/39fjQkb

I believe that buying quality ASX 200 shares is the best way to build your wealth over the long term. This is especially this case with interest rates looking to remain at historic lows for several years to come.

Here we look at 2 ASX 200 shares that I believe could make good additions to your share portfolio right now. Here’s why I recommend them:

2 ASX 200 shares to add to your portfolio

TPG Telecom Ltd (ASX: TPG)

TPG has struggled in recent years. This is partly due to the tight operating margins it faced when purchasing wholesale fixed broadband services from the National Broadband Network (NBN). This is reflected in its NBN average revenue per user (ARPU) figure. NBN ARPU has been steadily declining in recent years. It has dropped from $67.4 per month in 1H19 to $66.4 per month in 1H20.

However, I believe that TPG’s merger with Vodafone places it in a position to turn its fortunes around and drive higher profitability. TPG-Vodafone is now more strongly placed to compete with its two largest operators in the Australian telco market: Telstra Corporation Ltd (ASX: TLS) and Optus. In particular, the newly merged entity is well positioned to roll out a competitive 5G offering on Vodafone’s existing nationwide mobile network.

Transurban Group (ASX: TCL)

Transurban has unsurprisingly seen a reduction in traffic on its toll roads during the coronavirus pandemic. This triggered a sharp decline in it share price during the early phase of the crisis. The Transurban share price fell from $16.33 on 11 February to $10.50 on 20 March, a decline of 36%.

However easing of COVID-19 restrictions is resulting in a gradual recovery in traffic on Transurban’s tollways in local markets over the past few months. The company reported a steady recovery in traffic across its Australian operations, from mid April up until late June.

Melbourne of course is now in full lockdown mode again, and this will definitely slow down Transurban’s recovery over the rest of the year. However, I still remain optimistic about Transurban’s long-term  future. The coronavirus pandemic will eventually subside, with traffic levels returning to normal. Furthermore, Transurban’s two largest area of operation, Sydney and Melbourne, both have fast growing populations. They also both have expanding road systems that may require additional toll roads in the years to come. 

With the Transurban share price well below pre-COVID-19 levels, I believe that now could be a good opportunity to snap up some shares in this toll-road operator.

Foolish takeway

TPG and Transurban are two quality ASX 200 shares that I would be happy to add my portfolio right now. Both have faced recent challenges, however are now well placed for long-term growth.

More reading

• I would buy Coles and these ASX dividend shares right now
• Should infrastructure be part of your investment strategy?
• Why the Telstra share price is underperforming the market
• ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
• 4 ASX shares I’d buy to protect against a recession

Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Transurban Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post TPG and 1 other quality ASX 200 share to buy right now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30AkUen

ASX junior pharmaceutical company Mesoblast Limited (ASX: MSB) is one of the few companies to have delivered substantial gains to its shareholders during 2020. While big name healthcare shares like Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) have struggled throughout the COVID-19 pandemic, the Mesoblast share price has risen over 80% so far this year. It is also up an astounding 263% since bottoming out at $1.02 back in late March.

What’s been driving the Mesoblast share price?

Mesoblast uses stem cell technology to develop treatments for various inflammatory diseases including chronic heart failure and graft versus host disease (GvHD). GvHD is a complication which can occur in cancer patients who have received donor bone marrow or stem cells. It occurs when the donated ‘graft’ cells attack the patient’s own body cells and has the potential to be life-threatening.

Mesoblast’s GvHD treatment has been accepted for priority review by the United States Food and Drug Administration (FDA), with the potential for it to be made available in the US as early as September. The company announced on Tuesday that the Oncologic Drugs Advisory Committee, which advises the FDA, will review Mesoblast’s application in mid-August.

Additionally, one of Mesoblast’s treatments has shown promising results in treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS). The company is currently conducting a phase 3 trial involving 300 patients across North America in an attempt to prove the treatment’s efficacy.

Meanwhile, trials are also advancing to establish whether Mesoblast’s treatments are effective against advanced heart failure, lower back pain caused by degenerative disc disease and inflammatory lung disease, such as chronic obstructive pulmonary disease.

That seems like a lot of different fronts for the company to be advancing on simultaneously. As such, it’s no wonder Mesoblast has excited the market so much recently. And although some of these trials are still in their early stages, they do illustrate the broad potential of the company’s proprietary medical technology.

Mesoblast is also starting to show its commercial potential. Revenues for the first nine months of FY20 were US $31.5 million, a 113% increase over the same period in FY19. A successful capital raise in May means the company now has close to US $150 million in cash. It plans to put this cash towards launching its GvHD treatment in the US, pending the FDA approval, as well as scaling up manufacturing for its COVID-19 treatment.

Is the Mesoblast share price a buy?

While there is a lot of (justified) excitement around Mesoblast, this must be weighed against the potential risks. There is always the possibility that the FDA will not approve the company’s GvHD treatment for sale in the US, or that its treatment against ARDS will prove ineffective. There seems to be enough positive results coming out of its trials to make either, or both, of those scenarios seem unlikely – but they are still possible.

There is also the more likely potential that, considering the global focus that is directed towards the fight against COVID-19 right now, another treatment will come along that is more popular or effective against the respiratory complications caused by the virus. Mesoblast is only one of many companies from all over the world trying to develop an effective treatment against COVID-19.

However, notwithstanding these caveats, I still believe Mesoblast is an exciting investment and I’m bullish on its growth prospects. Despite a 10% surge in the Mesoblast share price yesterday, the company’s shares are still around 17% off the 52-week high of $4.45 they reached in late April.

With its commercial prospects rapidly improving, now could be a good time to snap up shares in this promising pharmaceutical company.

More reading

• Bring your portfolio to life with these ASX healthcare shares
• 3 of the best ASX blue chip shares you can buy right now
• 4 exciting ASX biotech shares surging higher today
• Why Afterpay, Ecofibre, Mesoblast, & Zip Co shares are racing higher
• Mesoblast share price climbs 9% on FDA meeting

Rhys Brock owns shares of Cochlear Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Mesoblast might be the best ASX healthcare growth share to own right now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2ZPtN4Q

If your portfolio hasn’t been performing as strongly as you would like this year, then now could be a good time to bring it to life with one of the top healthcare shares listed below.

I believe both have the potential to provide market-beating returns over the next few years, potentially making them great long term options today. Here’s why:

CSL Limited (ASX: CSL)

My favourite ASX healthcare share continues to be CSL. I think the biotherapeutics giant could be a fantastic long term option due to the quality and strength of its CSL Behring and Seqirus businesses. Its CSL Behring business is the global leader in plasma therapies, whereas its growing Seqirus business is the second largest influenza vaccines company globally.

I think both businesses have very positive outlooks thanks to their leading therapies and CSL’s heavy investment in research and development. In respect to the latter, this year the company will invest almost US$1 billion in its research and development efforts. I expect this to cement its leadership position and underpin strong long term earnings growth.

Nanosonics Ltd (ASX: NAN)

Nanosonics is the infection control specialist behind the popular trophon EPR disinfection system for ultrasound probes. This system has been growing its installed base at a rapid rate over the last few years and reached 22,500 units globally earlier this year. This installed base growth is positive for two reasons. This is because as its installed base grows, so too do the sales of the consumables that it requires.

For example, during the first half, consumables and service sales were up 40% on the prior corresponding period to $34.1 million. These recurring revenues represented 70% of its total revenue for the half. Pleasingly, its current installed base is still only a fraction of the global market opportunity estimated to be 120,000 units. Due to the quality of the product and favourable regulatory recommendations, I believe Nanosonics is well-placed to grow its market share materially over the next decade. This should be supported by the upcoming launch of several new products targeting unmet needs.

More reading

• Why Mesoblast might be the best ASX healthcare growth share to own right now
• Nanosonics and these ASX shares could be fantastic long term options
• 3 of the best ASX blue chip shares you can buy right now
• 3 investing strategies to profit from a second ASX share market crash in 2020
• Top fund manager names favourite ASX growth shares

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Bring your portfolio to life with these ASX healthcare shares appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/39ihbpK

The Resolute Mining Limited (ASX: RSG) share price will be on watch on Wednesday after the release of its second quarter production update.

How is Resolute performing in FY 2020?

For the quarter ending 30 June 2020, Resolute achieved gold production of 107,183 ounces at an all-in sustaining cost (AISC) of US$1,033 an ounce.

This was a 3% decline on production during the first quarter, but a 37% lift on production during the prior corresponding period.

During the quarter, Syama Sulphide gold poured lifted 64% to 35,248 ounces. This was supported by Syama Oxide gold poured of 28,457 ounces and Mako gold poured of 43,478 ounces.

Managing Director and CEO, John Welborn, commented: “I am particularly pleased with the performance of the Syama Underground Mine and Syama Sulphide operations during the June quarter.”

“We continue to focus on further improvements to Syama Underground and Sulphide operations while ensuring the positive performance in the June quarter is sustainable and sets a benchmark for quarterly performance from now on,” he added.

What about sales?

Resolute had a strong quarter of sales. It sold 110,660 ounces of gold, up 8% from the March quarter.

Positively, it experienced a 3% quarterly rise in its average realised price to US$1,446 an ounce. Based on its AISC of US$1,033 an ounce, this gives Resolute a margin of US$413 an ounce.

Which, when multiplied with its 110,660 ounces of gold sold, equates to an operating profit of approximately US$45.7 million.

Outlook.

Looking ahead, the company believes it is on target to achieve its FY 2020 guidance of 430,000 ounces at an AISC of US$980 an ounce.

Mr Welborn said: “Production of 107,183oz of gold during the June quarter meets our expectations and results in year to date production to 217,946oz placing the Company in a strong position to deliver our full year guidance of 430,000oz.”

“We expect to continue to improve production and deliver lower costs at Syama in the second half of 2020 while we evaluate further value enhancements and exciting exploration opportunities.”

More reading

• Why the BlueScope share price is outperforming today
• Why De Grey, Resolute, Suncorp, & Webjet shares are dropping lower

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Resolute Mining share price on watch after solid Q2 update and guidance confirmation appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30xO1ix